alexa Oral Ribavirin Treatment Failure for Severe Parainfluenza Type 1 Infection in a Patient with End Stage Interstitial Lung Disease Successfully Treated with DAS181 | Abstract
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Case Report

Oral Ribavirin Treatment Failure for Severe Parainfluenza Type 1 Infection in a Patient with End Stage Interstitial Lung Disease Successfully Treated with DAS181

Bogdanovich T1, Kwak EJ1, Silveira FP1, Pakstis DL1, Lanza P2*, and Moss RB2

1Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA, USA

2Ansun Biopharma, Inc., San Diego, CA, USA

*Corresponding Author:
Lanza P
Ansun Biopharma, Inc., 3030 Callan Road
San Diego CA 92121, USA
Tel: 858-452-2631
Fax: 858-452-0133
E-mail: [email protected]

Received Date: January 27, 2016; Accepted Date: February 18, 2016; Published Date: February 28, 2016

Citation: Bogdanovich T, Kwak EJ, Silveira FP, Pakstis DL, Lanza P, et al. (2016) Oral Ribavirin Treatment Failure for Severe Parainfluenza Type 1 Infection in a Patient with End Stage Interstitial Lung Disease Successfully Treated with DAS181. J Antivir Antiretrovir 8:020-022. doi:10.4172/jaa.1000130

Copyright: © 2016 Lanza P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Parainfluenza virus (PIV) infections can cause serious respiratory infections and death in immunocompromised patients. No antiviral drugs have proven efficacy against PIV. DAS181, a sialidase fusion protein has been shown to inhibit infection with PIV strains both in vitro and in animal model. The clinical course of immunocompromised patients with PIV-1 infection is described. After being diagnosed with PIV infection, patient was treated for 18 days with oral Ribavirin (RBV) but failed to respond clinically and no virus clearance was obtained. However, patient tested negative for PIV after a 10-days DAS181 treatment course. This case exemplifies failure of oral RBV treatment of severe Parainfluenza virus infection and subsequent viral clearance associated with administration of inhaled DAS181. Large scale randomized trials are warranted to determine the therapeutic efficacy of DAS181 against PIV related lung disease.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7